PUM2

Across TCGA pan-cancer cohorts, PUM2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PUM2 data layer compared with 29 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher PUM2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PUM2 expression acts as an unfavorable survival marker.

OV, ESCA, and LUAD are the cancer types where PUM2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.290	0.693	.001	18	view →
ESCA	OS	Median	All	0.160	0.704	<.001	18	view →
LUAD	OS	Median	II,III,IV	0.254	0.754	.001	13	view →
PCPG	DFS	Median	All	0.080	0.768	<.001	6	view →
PRAD	DFS	Median	All	0.187	0.775	.008	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PUM2–OV (OS)

Open the OV breakdown →